Rorer Pharmaceutical Corporation

Rhone-poulenc Rorer Pharmaceuticals Inc.

Jeffrey C Pelletier

Henry F Campbell

Raymond D Youssefyeh

Bruce F Molino

Scott I Klein

Charles J Gardner

Mark Czekaj

Michael R Becker

Jeffrey M Dener

This invention relates to novel peptide and pseudopeptide derivatives and analogs of aspartic acid which are useful as inhibitors of platelet aggregation and thrombus formation in mammalian blood, to pharmaceutical compositions including such compounds, and to their use in inhibiting thrombus formation and platelet aggregation in mammals.

Antithrombotic peptides and pseudopeptides

This invention relates to a series of bicyclic benzomonoazacyclic carboxamide compounds of the general formula: ##STR1## Where Z is tertiary amine, which are useful for the method of treating patients suffering from gastrointestinal disorders, and of pharmaceutical composition including an effective 5HT3 - antagonists amount of said compounds therein.

Substituted saturated and unsaturated indole quinoline and benzazepine

Disclosed are novel peptides and pseudopeptides and pharmaceutical compositions thereof that inhibit platelet aggregation and thrombus formation in mammalian blood.

Anti-thrombotic peptides and pseudopeptides

This invention relates to benzoxazine and benzoxazepine carboxamide compounds which exhibit 5-HT.sub.3 antagonist properties including CNS, anti-emetic and gastric prokinetic activity and which are void of any significant D.sub.2 receptor binding affinity. This invention also relates to pharmaceutical compositions and methods for the treatment of gastrointestinal and mental disorders using said compounds.

Benzoxazine and benzoxazepine carboxamide 5-HT.sub.3 antagonists

This invention relates to heteroazabenzo-bicyclic substituted carboxamide compounds of the formula: ##STR1## where W is O, S or NR.sub.5 and

Heteroazabenzobicyclic carboxamide 5-HT.sub.3 antagonists

Certain specific substituted benzobicyclic carboxamides and their valuable use as 5-HT3 antagonists having CNS and gastric prokenetic activity void of any significant D.sub.2 receptor binding activity are disclosed.

Benzobicyclic carboxamide 5-HT3 antagonists

Certain specific substituted azabicyclic carboxiamides and their valuable use as 5-HT3 antagonists having CNS and gastric prokenetic activity void of any D.sub.2 receptor binding properties are disclosed.

Growing community of inventors

Lansdale, PA, United States of America

Jeffrey C Pelletier